Schrodinger, Inc.
SDGR
Positions held
Your positionsSDGR isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Schrodinger, Inc. operates in the growing health information services sector, leveraging advanced computational platforms to enhance drug discovery and development processes.
- Revenue for Q2 2026 was $58.889 million, showing a 1% increase compared to the prior quarter.
- Gross margin improved to 55.1% from 50.4% in the previous quarter.
- The company has a high debt-to-equity ratio of 32.832, indicating potential financial risk.
- Operating margin for Q2 2026 was -70.6%, reflecting ongoing challenges in profitability.
- Net income for 2025 was -103.265 million, highlighting significant losses over the year.
Fundamentals
| Market cap | $1.97B | Enterprise value | $1.67B | Trailing P/E | — | Forward P/E | -19.55 |
| PEG | — | Price / book | 5.85 | Beta | 1.62 | Dividend yield | 0.00% |
| Revenue growth | 7.5% | Earnings growth | — | Gross margin | 56.9% | Operating margin | -70.6% |
| Profit margin | -21.0% | ROE | -16.2% | ROA | -14.4% | Debt / equity | 0.33 |
| Current ratio | 2.71 | Free cash flow | -$29.16M | Analyst recommendation | none | Mean target | $21.43 |
| 52w high | $33.78 | 52w low | $10.95 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $58.9M | $58.6M | $87.2M | $54.3M | $54.8M | — |
| Op margin | -70.6% | -83.3% | -19.7% | -84.6% | -96.6% | — |
| Net income | $6.0M | -$60.0M | $32.5M | -$32.8M | -$43.2M | — |
| Gross margin | 55.1% | 50.4% | 65.7% | 51.6% | 47.8% | — |
| Gross profit | $32.4M | $29.5M | $57.3M | $28.0M | $26.2M | — |
| Operating income | -$41.5M | -$48.8M | -$17.2M | -$45.9M | -$52.9M | — |
- Revenue +1% vs prior quarter ($59M vs $59M).
- Gross margin 55.1% (was 50.4% prior quarter).
- Operating margin expanded to -70.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $256M | $208M | $217M | $181M | — |
| Op margin | -65.2% | -100.8% | -81.9% | -81.1% | — |
| Net income | -$103M | -$187M | $40.7M | -$149M | — |
| Gross margin | 55.7% | 63.6% | 64.9% | 55.8% | — |
| Gross profit | $143M | $132M | $141M | $101M | — |
| Operating income | -$167M | -$209M | -$177M | -$147M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · What Could Go Wrong With Recursion Pharmaceuticals Stock?
2026-10-06 · Schrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?
2026-09-27 · Schrödinger (SDGR) Could Be 29% Below Fair Value Despite A 38% Overvalued View
2026-09-24 · Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
2026-09-23 · Schrodinger Stock Has Technical Strength as It Hits New 2-Year Highs
2026-09-21 · Schrodinger Insider Sold Shares Worth $927,970, According to a Recent SEC Filing
2026-09-18 · Why DataMEDS’ Acquisition Does Not Seem to Be Very Bullish for MEDS Stock at This Point
2026-09-18 · SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?
2026-09-17 · Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-16 · Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?
2026-09-09 · Schrodinger Establishes Tectora Therapeutics With RA Capital, New Enterprise Associates
Price (daily)
Full chart · RSI · MACD · patterns